Open AccessReal‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
Author(s) -
Gendron Nicolas,
FeralPierssens Anne Laure,
Jurcisin Igor,
Raucourt Emmanuelle,
Bouton Valerie,
Fischer Anne Marie,
LorenceauSavale Camille,
LilloLe Louët Agnès,
Smadja David M.
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.839
Subject(s) - idarucizumab , medicine , dabigatran , antidote , anticoagulant therapy , major bleeding , complication , intensive care medicine , anticoagulant , oral anticoagulant , surgery , anesthesia , warfarin , atrial fibrillation , toxicity
Key Clinical Message Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.